Physician profile
Robert L Corder
NPI 1770508327
$635.94
in general payments reported to CMS, 2019-2025
11 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Addiction Medicine (Family Medicine) provider received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.42 · 2021: $23.99 · 2022: $91.16 · 2023: $132 · 2024: $210 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $469.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $147.71 | 2022-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $112.26 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $103.02 | 2023-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $88.38 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.22 | 2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $35.02 | 2024 | Fanapt, Hetlioz |
| Orexo US, INC. | $34.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.93 | 2022-2023 | Spravato |
| Axsome Therapeutics, INC. | $18.05 | 2023 | Auvelity |
| Indivior INC. | $17.32 | 2019 | |
| Abbvie INC. | $13.93 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Corder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.